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ABSTRACT:
In contrast to extensive studies on familial breast cancer, it is currently unclear 
whether defects in DNA double strand break (DSB) repair genes play a role in 
sporadic breast cancer development and progression. We performed analysis of 
immunohistochemistry in an independent cohort of 235 were sporadic breast tumours. 
This analysis suggested that RAD51 expression is increased during breast cancer 
progression and metastasis and an oncogenic role for RAD51 when deregulated. 
Subsequent knockdown of RAD51 repressed cancer cell migration in vitro and reduced 
primary tumor growth in a syngeneic mouse model in vivo. Loss of RAD51 also 
inhibited associated metastasis not only in syngeneic mice but human xenografts 
and changed the metastatic gene expression profile of cancer cells, consistent with 
inhibition of distant metastasis. This demonstrates for the first time a new function 
of RAD51 that may underlie the proclivity of patients with RAD51 overexpression to 
develop distant metastasis. RAD51 is a potential biomarker and attractive drug target 
for metastatic triple negative breast cancer, with the capability to extend the survival 
of patients, which is less than 6 months. 
INTRODUCTION
The molecular transformation of normal breast 
epithelia to tumor requires the accumulation of a number 
of mutations in key metabolic pathways. This is most 
readily achieved by deregulation of cellular DNA repair 
pathways, resulting in increased genomic instability. The 
aggressive triple negative breast cancer (TNBC) subtype 
lacks expression of hormone receptors (ER, PR and 
HER2) and therefore progression is determined by specific 
molecu lar aberrations critically important for cell survival. 
We hypothesised that aberrant DNA damage response 
(DDR) may drive and contribute to metastatic progression 
of sporadic TNBC. 
Much of the evidence linking defective DNA 
damage response (DDR) with breast cancer susceptibility 
comes through studies of familial breast cancer. Many 
of the breast cancer predisposition genes identified 
that mediate homologous recombination (HR) repair 
of DNA damage, including BRCA1 and BRCA2, are 
mutated or epigenetically silenced [1, 2]. However, no 
inactivating mutations of RAD51, a crucial HR protein, 
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have been reported in tumours. Paradoxically, Rad51 is 
overexpressed in multiple tumor types, including breast 
cancer [3]. Overexpression of RAD51 is due to increased 
transcription, reduced methylation and/or stabilization 
of the protein but not due to amplification of the RAD51 
gene [4, 5]. Overexpression of RAD51 has also been 
suggested as a driver of aberrant recombination, resulting 
in excess DNA damage in precancerous cells. These drive 
pathological recombination events such as chromosomal 
amplifications, deletions and translocations resulting in 
loss of heterozygosity and aneuploidy. These events can 
lead to cancer development and progression to metastasis 
[6, 7]. Cells that overexpress RAD51 exhibit disruption of 
cell cycle, resistance to apoptotic signals and associated 
resistance to DNA damaging agents (radiotherapy) and 
chemotherapy [8-10]. Hence depletion of RAD51 by 
siRNA and shRNA results in potential sensitization to 
various agents as seen in radiation treatment of pancreatic 
cancer and multiple myeloma [11], and in combination 
therapies for non small cell lung cancer (NSCLC) with 
gemcitabine [12] and glioma with temozolomide [13]. 
However, despite these studies, the molecular mechanisms 
of RAD51-mediated cancer progression have not been 
fully elucidated. 
We utilized in silico analysis of gene expression 
datasets, clinical pathology and cellular biology studies 
to show that one of the DNA repair genes RAD51 was 
over represented in high grade and metastatic breast 
carcinomas. We also utilized animal models to show 
that RAD51 is required for metastasis and discovered 
that RAD51 is a potential transcriptional co-factor of 
c/EBPβ and supports metastatic expansion of cancer 
cells via regulating changes in gene expression. These 
are important discoveries for the development of new 
therapeutic regimes and for successful treatment of 
aggressive breast cancer, in particular metastases.
RESULTS
RAD51 expression correlates with high-grade 
metastatic breast tumors and poor prognosis
Increased RAD51 expression has been correlated 
with poor clinical outcome in lung cancer, prostate cancer 
and in ER+ breast cancer [14-17]. Comparison of breast 
cancer cell lines revealed that RAD51 protein expression 
was at two fold or higher in 9 of 12 (75%) triple negative 
cell lines, 1 of 5 (20%) luminal and 2 of 3 (67%) HER2+ 
breast cancer cell lines when compared to the MCF10A 
cell line (near normal mammary epithelial cell line 
derived from a patient with benign fibrosarcoma)(Data 
not shown). An example of the difference in expression 
in triple negative breast cancer cell lines versus luminal is 
shown in Figure 1A. Of note we found RAD51 expression 
levels to be independent of both proliferation rate of 
the cells (R2=0.0012, confirmed by contrasting RAD51 
expression to S-phase regulated genes PCNA /Geminin) 
and RAD51 functional status with varied formation of 
foci in response to irradiation (Supplementary Figure 
1A-C). To validate our cell line data, we proceeded to 
evaluate RAD51 expression by immunohistochemistry 
in an independent cohort of 235 were sporadic tumours 
(Figure 1B). We found overall that 42/235 (17.8%) were 
positive for nuclear RAD51. In the ILC cases with lymph 
nodes metastases (LN mets), we found a significant 
enrichment of nuclear RAD51 in metastatic compared to 
the primary tumors (p=0.047, Figure 1B). Moreover, in 23 
cases of matched in situ carcinoma, invasive carcinoma 
and LN metastases from the same patients, RAD51 levels 
increased with higher stage lesions (p=0.003, Figure 
1B). We also investigated RAD51 expression in a series 
of matched primary IDC and brain metastasis from the 
same patients (n=39). Interestingly we observed a higher 
frequency of positivity in these distant metastases (17/39, 
43%) compared to the primary tumors (8/39, 20%), which 
approached significance (p=0.0512, Figure 1C). We next 
investigated RAD51 mRNA expression and correlation 
with histopathological parameters in the METABRIC 
(Molecular Taxonomy of Breast Cancer International 
Consortium) dataset [18]. Fifty two percent of tumours had 
high RAD51 mRNA expression, which was significantly 
associated with aggressive clinicopathological features 
(Supplementary Table 1), including diagnosis at younger 
age, high histological grade, high proliferation index, 
HER2-overexpression, absence of hormonal receptors 
(ER/PR), presence of basal like phenotypes and triple-
negative phenotypes (Supplementary Table 1). RAD51 
expression was higher in tumors with TP53 mutation 
and correlated with worse overall survival at 3 and 5 
years (Supplementary Table 1). Overall in silico revealed 
similar RAD51 expression trends to those observed with 
cell lines and patient immunohistochemistry, consistent 
with the notion that RAD51 expression is increased during 
breast cancer progression and metastasis, suggesting 
an oncogenic role when deregulated. Consistent with 
previous work [3] our observations demonstrate RAD51 
is more highly expressed in aggressive breast cancer when 
compared to normal tissue.
RAD51 knockdown affects metastasis in a 
syngeneic tumor model in vivo
Next, we investigated the functional contribution 
of RAD51 to primary tumour growth and metastasis 
formation in vivo. using 4T1.2 cells, (a syngeneic mouse 
mammary tumour model of spontaneous metastasis). 
We engineered the 4T1.2 lines to express a doxycycline 
regulated shRNA targeting Rad51. The pooled 
transfectants showed reduced RAD51 protein expression 
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by 70-80% (Fig 2A), with no change in cell growth with 
RAD51 depleted cells doubling rate 32.3 hours versus SCR 
control cells 28.6 hours (p=0.067) and viability compared 
to cells transfected with a scrambled shRNA as a control 
(Fig 2B). Both cell lines expressing the firefly luciferase 
gene were orthotopically implanted into mammary fat 
pads of immunocompetent mice to determine if RAD51 
knockdown impacts on primary tumour growth and/or 
metastasis. The depletion of RAD51 expression in 4T1.2 
cells lead to a significant delay in primary tumor growth 
in vivo (p=0.0013)(Fig 2C), with sustained depletion of 
RAD51 at the primary site and overexpression observed in 
metastatic tumours (Supplementary Figure 2). Luciferase 
levels representing the presence of tumour cells in distant 
organs were decreased in mice transplanted with shRAD51 
4T1.2 cells as compared to shControl 4T1.2 cells (SCR) at 
day 14 (Fig 2D), even when the luciferase activities were 
normalized to the decreased primary tumor size observed 
with shRAD51 4T1.2 cells. We hypothesize that the 
observed delay in metastasis was due to poor seeding and 
growth of the RAD51 depleted cancer cells at secondary 
sites. To analyse whether RAD51 is required to support 
metastatic cell growth we repeated the above experiment 
after resection of same size primary tumours. As expected 
from the above data, depletion of RAD51 expression 
in the absence of the primary tumour inhibited onset 
of metastatic lesions. After 14 days RAD51 depletion 
resulted in regrowth of tumor at the original primary site 
compared with control mice that displayed disseminated 
metastatic tumours to the bone and brain (Figure 3A). 
Overall tumour burden median was lower in the RAD51 
depleted cohort compared to the control cohort (Figure 
3B). This correlated with a significant increased survival 
advantage for the RAD51 depleted cohort (p=0.025)
(Figure 3C). 
Figure 1: High RAD51 expression is observed in basal breast cell lines and metastatic patient samples. (A) Ten breast 
cancer cell lines were analysed for RAD51 protein expression. Triple negative breast cancer lines are marked with an asterix. (B) 235 
primary breast cancers were analysed by tissue microarray for RAD51 expression. P vales were obtained using Chi squared test with 
Yates correction (95% confidence interval) and Fisher’s exact test to compare RAD51 status between defined subgroups of samples. (C) 
Histological comparison of RAD51 expression shows high levels in metastatic lymph node tissue samples (right panels) compared to 
matched primary breast tumor (left panels -100X magnification, bar 50µm).
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Figure 2: Depletion of RAD51 inhibits tumor growth and metastatic progression in a syngeneic murine breast cancer 
model. (A) Knockdown of RAD51 protein expression was achieved using an inducible RAD51mir construct after 48 hours exposure 
to 5µg/ml Doxycycline. (B) Viability of 4T1.2 cells induced with doxycycline for 7 days with and without depletion of RAD51 were 
analysed by propidium iodide uptake. (C) Depletion of RAD51 was induced in cohorts of 10, 5 week-old female Balb/C mice with 5µg/
ml Doxycycline after establishing 40mm3 tumors from 1x106 cells of 4T1.2-RAD51mir and 4T1.2-SCRmir injected into the mammary fat 
pad. Cohorts were monitored for tumor growth over 18 days, with uninduced mice serving as controls *p=0.0013 +SD. (D) Primary tumor 
and metastatic burden was also followed by luciferase expression. 
Figure 3: RAD51 supports metastatic burden in vivo. Cohorts of 10, 5 week-old female Balb/C were induced with 5µg/ml 
Doxycycline after establishing 40mm3 tumors from 1x106 cells of 4T1.2-RAD51mir and 4T1.2-SCRmir injected into the mammary 
fat pad. Primary tumours were resected and tumour burden followed for 2 weeks. (A) Tumours competent for RAD51 spontaneosuly 
metastasized, while tumours depleted of RAD51 only re-established at the primary site. (B) Mice with tumours competent for RAD51 
displayed higher median tumour burden (black) compared to mice harbouring tumours depleted of RAD51 (red) as measured by total 
luminescence *p=0.024 +/-SEM. (C) The RAD51 knockdown cohort displayed a significant survival advantage (red line) compared to the 
control RAD51 competent cohort (black line) (p=0.025) +/-SEM.
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Loss of RAD51 inhibits metastatic seeding of 
xenografts in-vivo
In order to further study the metastasis-inhibitory 
effect of Rad51 in human breast cancer cells, MDA-
MB-231 cells harbouring a stable integration of the 
inducible shRAD51 were injected into separate cohorts 
of immunocompromised mice by orthotopic implantation 
and via tail vein injection after inducing knockdown 
of RAD51 for 96-hours with doxycycline (4 µg/ml) 
(Figure 4A). Growth of the primary tumor and seeding 
of secondary sites was monitored by bioluminescence 
imaging. Depletion of RAD51 expression did not 
significantly reduce proliferation rates of the MDA-
MB-231 cells in vitro (p=0.221) (Figure 4B) and primary 
tumour growth was not affected in vivo (Figure 4C), with 
no significant difference in proliferation as measured by 
immunostaining of Ki67 (Figure 4D). In the tail vein 
injection group, successful implantation of RAD51 
competent and depleted cells in lungs was recorded on 
day 1, yet after 14 days none of the mice transplanted with 
RAD51 depleted cells displayed colonization in either 
the brain, bone or lung compared to 56% of the mice in 
the control group (Figure 4E). Of note after a further 14 
days (day 28) only 50% of mice transplanted with RAD51 
Figure 4: Depletion of RAD51 inhibits metastatic seeding of the lungs in-vivo. (A) Western blot analysis of knockdown of 
RAD51 protein expression using an inducible RAD51mir construct after 96 hours exposure to 5µg/ml Doxycycline. (B) Comparison of 
growth rate between MDA-MB-231 cells depleted of RAD51 and scrambled controls revealed no significantly affect in proliferation in 
vitro over 2 weeks (p=0.171) +/- SEM. (C) Primary tumour volume was monitored by changes in luciferase signal in cohorts of 10 mice 
over 2 weeks. Knockdown of RAD51 did not affect primary tumour growth of MDA-MB-231 cells transplanted into the mammary fat 
pad % tumour volume change +/-SD. (D) Histological analysis of mammary tumours show that knockdown of RAD51 did not affect 
growth rate in vivo as measured by Ki67. Results are quantification of 5 fields of 2 tumours of each cohort, +/- SEM (p=0.260). Images 
are 100X magnification. (E) Analysis of xenograft seeding and potential metastatic dissemination of MDA-MB-231 cells show that 1x106 
doxycycline induced RAD51 depleted cells injected intravenously were able to seed the lungs initially but after 14 days were unable 
dissemination and form metastases. 
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depleted cells developed metastases compared with 89% 
of the control mice. To gain mechanistic insights on the 
role of RAD51 in promoting the colonization of secondary 
sites, we focused on phenotypic changes induced by 
knockdown of RAD51 in MDA-MB-231 cells. Metastatic 
colonization of basal breast cancers can require reversion 
from a mesenchymal to a more epithelial like phenotype 
(MET transformation) and change in stem-ness promoting 
migration and survival. After 7 days of knock-down of 
RAD51 in MDA-MB-231 cells, we observed a change 
in morphology in a sub-population of cells consistent 
with a more epithelial, flattened shape and possible MET 
via actin cytoskeletal rearrangement (Supplementary 
Figure 3A). However there was no corresponding 
change in expression of stem cell markers CD24/CD44 
(Supplementary Figure 3B) and vimentin or E-cadherin 
at the cell-cell junction (Supplementary Figure 3C) or 
doubling rate (Supplementary Figure 3D). Taken together 
these results suggest that RAD51 depletion is able to delay 
colonization/ seeding at secondary sites, via a mechanism 
that alters actin cytoskeleton with negligible impact on 
mesenchymal phenotype/ stemness of the cells. 
To confirm a role for RAD51 in breast cancer 
metastasis in vivo, BT549 cells that had been engineered 
to express firefly luciferase were transfected with RAD51 
expression plasmid or empty vector (EV) (Figure 5A). The 
gain of function increased the migration rate of the cell 
line as measured by transwell assays (Figure 5B). Next 
we assessed the degree of spontaneous liver metastasis by 
orthotopic implantation. As previously observed, BT549 
Figure 5: RAD51 can transform poorly metastatic cells. (A) Western blot analysis performed on human BT549 engineered for 
overexpression of RAD51. (B) Analysis of the migration potential of the overexpressing line and control lines was examined over 72 
hours. (C) Cohorts of 10, 5 week-old nude (NU-Foxn1nu) mice were injected into the mammary fat pad with poorly metastatic BT549 
line overexpressing RAD51 or a control empty vector. Tumour cell dissemination was monitored by luciferase expression. (D vs E) 
Mice harbouring overexpressing tumour cells displayed increased liver weight but not spleen weight +/-SEM. (F) Metastatic burden was 
confirmed by vimentin positive colonies in the liver.
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established low level of spontaneous metastases in the 
liver [19] and enhanced RAD51 expression resulted in 
a significant increase in metastatic burden in the liver 
compared to the control cohort (EV) (Figure 5C). This was 
not observed in the spleen (Figure 5D vs 5E). Each cohort 
of 10 mice was examined and 1 mouse in the control 
cohort had vimentin positive macro-metastases while 6 
mice in the Rad51 overexpressing cohort had vimentin 
positive macro-metastases (Figure 5F). Taken together 
these results indicate that RAD51 depletion suppressed 
the metastatic spread of MDA-MB-231 cells and RAD51 
overexpression enhanced the metastatic spread of BT549 
cells, suggesting that RAD51 increases the metastatic 
potential of breast cancer in vivo. 
RAD51 regulates metastatic gene expression as a 
possible transcriptional co-factor
The change in cell morphology of sub-population of 
RAD51-depleted cells, motivated us to determine whether 
RAD51 expression level affects metastasis via changes in 
both migration potential and gene expression; including 
cell adhesion, extracellular matrix, proliferation and/
or transcription factor genes. Knockdown of RAD51 in 
MDA-MB-231 cells impeded migration (Supplementary 
Figure 3A), while overexpression in Hs578t cells enhanced 
migration (Supplementary Figure 3B). We also observed 
increased expression of c/EBPβ in both Hs578t and BT549 
cells overexpressing RAD51 (Supplementary Figure 4). 
Next we performed a metastasis specific gene expression 
array on the same cell lines. A total of 82 genes previously 
implicated in processes relevant to tumor progression 
were screened, of which 25 were selectively induced with 
overexpression of RAD51 and repressed with knockdown 
of RAD51 (Supplementary Fig 5C). In particular, reduced 
RAD51 expression correlated with increased expression 
of genes that inhibit metastatic invasion, including; CCL7, 
BRMS1, NME4 and TIMP3, and a corresponding decrease 
in expression of genes promoting metastatic invasion and 
proliferation; MMP13, MMP11, MMP10, MMP3, MMP7, 
MTA1, IL1β, TCF20, and oncogenes H-RAS, K-RAS, 
MDM2 and the mutated form of TP53. Four (namely, 
MMP2, MET, NF2 and TP53) of the 25 identified genes 
are expressed in aggressive lung metastases from breast 
cancer [20]. We also confirmed upregulation of 8 of the 
25 genes in BT549 cell line overexpressing RAD51 that 
showed enhanced metastatic spread to the liver in mice. 
We also determined that 5 (MMP11, MMP13, SMAD2 
TGFβ, TP53) of the 25 are regulated by the transcription 
factor CCAAT/enhancer binding protein beta (c/EBPβ) 
when further analysed for transcription factor binding 
motifs using Ingenuity analysis. 
RAD51 is required for transcriptional activity of 
c/EBPβ 
 c/EBPβ is important for mammary gland 
development and its expression is deregulated in breast 
cancer [21]. RAD51 has previously been shown to act as a 
co-factor for c/EBPβ and augment its ability to modulate 
basal and Tat-induced activation of HIV-1 LTR [22]. We 
confirm for the first time in breast cancer cells that RAD51 
and c/EBPβ interact in situ (Figure 6A) and confirmed 
this by co-immunoprecipitation of endogenous proteins 
(Figure 6B). RAD51 expression levels also determines c/
EBPβ transcriptional activity with up to 80% reduction 
in activity observed with depletion of RAD51 using 
two differently targeting RNAi constructs (p=2.8x10-9) 
(Fig 6C). To confirm RAD51 associated changes in 
expression of c/EBPβ target genes we performed 
chromatin immunoprecipitation (ChIP) of c/EBPβ at the 
target genes identified in array in MDA-MB-231 cells 
with or without knockdown of RAD51. After depletion 
of RAD51 there was a reduction in the enrichment of 
c/EBPβ at the promoter of MMP11, MMP13, TGFβ 
and SMAD2 (Supplementary Figure 6). Interestingly, 
targeting of RAD51 by two different siRNAs directed 
against different regions of RAD51 lead to an associated 
downregulation of c/EBPβ protein (Fig 6D). We also 
observed co-regulation of expression with some reduced 
mRNA expression of c/EBPβ after depletion of RAD51 
(Fig 6E). This suggests that RAD51 and c/EBPβ exist 
as a part of complex wherein RAD51 likely controls c/
EBPβ transcription affecting metastatic gene expression 
levels and the pro-metastatic cell phenotype profile. The 
molecular mechanism by which this occurs represents a 
new function for a DNA damage response protein and is 
part of ongoing research.
DISCUSSION
Although DNA repair proteins are considered 
fundamental to the development of breast cancer, 
their contribution in pathogenesis of sporadic breast 
cancer remains an understudied area. Using cell line, 
immunohistochemistry, in silico and animal model analysis 
we find that high RAD51 expression correlates with 
aggressive breast cancer and its loss retards metastasis. We 
also observed high RAD51 expression in conjunction with 
p53 mutation or loss. This provides an additional driver of 
mutation and a likely mechanism for overexpression via 
loss of p53-mediated repression of RAD51 at the RAD51 
promoter [9, 23]. RAD51 also contains FoxM1 binding 
sites in its promoter and its expression can be regulated 
in glioblastoma by this transcription factor [24]. Although 
RAD51 also contains promoter-binding sites for c/EBPβ, 
it is currently not known to regulate RAD51 expression 
in the cancer setting. Interestingly c/EBPβ can repress 
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p53 expression [25] suggesting a possible mechanism for 
RAD51 overexpression. Thus, the mechanism of increased 
transcriptional upregulation of RAD51 in cancers has 
not been fully defined but it is unlikely to involve gene 
amplifications or fusions [26]. Using breast tissues TMA, 
we confirmed that high level of RAD51 correlates with 
advanced histological grading in breast cancer, consistent 
with a previous report [3].. Notably, RAD51 is highly 
expressed in matched lymph node and brain metastasis 
compared to primary tumor. Overall, these data indicate 
that RAD51 overexpression might have significant impact 
on progression and metastasis of breast cancer. 
Overexpresison of DNA damage response genes 
are known to support cancer [9]. However DNA damage 
proteins have not previously been strongly linked with 
metastatic progression. We show that RAD51 is crucial 
not only for primary tumor growth but also metastatic 
spread of 4T1.2 cells. Using tail vein assay of cancer 
metastasis in MDA-MB231 cells, we show that RAD51 
dramatically promotes appearance of lung metastasis. 
Notably, these results cannot be explained by effect of 
RAD51 on cell growth, as RAD51 depletion did not effect 
cell proliferation and doubling time in vitro and primary 
tumor growth in vivo in MDA-MB231 xenografts. 
Strikingly, overexpression of RAD51 in BT549 cells 
significantly increased spontaneous metastasis to liver. 
The data presented here constitute the first direct evidence 
of the role of RAD51 promoting or enhancing metastastic 
progression. 
Consistent with changes in metastatic potential, 
Figure 6: RAD51 forms a complex with the transcription factor c/EBPβ. (A) A DuolinkTM proximity ligation assay was used to 
analyse close proximity of RAD51 and c/EBPβ in MDA-MB-231 cells in situ (<40nm). The interaction between RAD51 and c/EBPβ was 
observed at similar levels as the BRCA2 positive control. (B) Coimmuniprecipitation of endogenous c/EBPβ and RAD51 was performed in 
MDA-MB-231 cells with recipricol antibodies. (C) A c/EBPβ reporter activity construct was used in MDA-MB-231 to analyse the effect of 
RAD51 knockdown on c/EBPβ transcription. Using two independent RAD51 targeting RNAi significantly inhibited c/EBPβ transcription 
(p<0.0001). (D) Western blot analysis of protein expression levels using RNAi directed towards both c/EBP and RAD51 was performed 
in MDA-MB-231 cells. The knockdown of RAD51 resulted in loss of c/EBPβ expression to comparable levels using targeted siRNA. (E) 
Analysis of gene expression using qRT-PCR. Knockdown of RAD51 resulted in associated loss of c/EBPβ mRNA expression in MDA-
MB-231 cells. Experiments C and E are plotted as average of 3 independent experiments ±SEM.
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we found that RAD51 increases the expression of 
prometastatic genes and reduces the expression of 
metastasis suppressor genes. Amongst these were several 
c/EBPβ target genes. We further demonstrated that RAD51 
and c/EBPβ exist as part of a complex wherein RAD51 
controls c/EBPβ transcription. Consistent with this c/
EBPβ binding at its target genes and transactivation of 
c/EBPβ reporter was reduced in RAD51 depleted cells. 
Our array also defined target genes of c/EBPβ (regulated 
by RAD51 expression) that are required for invasion. 
Stromal cells largely express MMPs, however we find 
distinct changes in their expression in breast cancer 
cell lines. It is suggested that cancer cell lines that have 
already undergone epithelial-mesenchymal transition, such 
as triple negative breast cancer cells up regulate MMPs 
as part of promoting cell motility, leading to migration 
from the primary tumour and intravasation [27]. This has 
also been observed in xenografts of human breast cancer 
cell lines [28]. We find that both MMP11 and MMP13 
levels are regulated by RAD51 expression. MMP13 is 
upregulated in metastatic breast cancer patient samples 
[29] and is part of a gene signature that is a predictor of 
prognosis in breast cancer lymph node metastasis [30]. 
Thus it appears that RAD51 has two distinct 
roles in promoting metastasis; the first is based on the 
increased repair and stabilizing the cancer genome 
allowing spread of tumor cells [8, 9] and the second as 
a regulator of c/EBPβ in promoting pro-metastatic gene 
expression. The stabilization of the cancer genome 
means that deregulated RAD51 is promoting aberrant 
DNA repair that allows advantageous mutations beyond 
those required for primary tumors. For example ectopic 
overexpression of RAD51 protein in mouse embryonic 
stem cells leads to a novel spectrum of recombination 
events, including multiple chromosome rearrangements 
and aneuploidy [7]. The second role regulates metastasis, 
via modulation of gene expression as a cofactor for c/
EBPβ. c/EBPβ transcriptional activity is determined by 
the levels of isoforms LAP1, LAP2 and LIP. LIP forms 
suppressive heterodimers with the other isoforms. c/
EBPβ has been associated with hematopoietic and 
adipocyte differentiation [31, 32] and implicated as an 
essential mediator of mammary gland development[33]. 
Therefore we can assume that c/EBPβ is able to regulate 
gene expression in breast tissue resulting in growth 
and differentiation. Indeed in the breast cancer setting, 
deregulation of LIP function contributes to escape of 
cytostatic effects of TGFβ and contributes to tumour 
metastasis [33-36]. We observe that RAD51 is strongly 
associated with breast cancer pathology progression, high-
grade tumours and metastasis. The combination of RAD51 
contributing to enhancing c/EBPβ expression efficiency 
is undeniably a potent combination in driving metastatic 
progression. Supporting this hypothesis is the number 
of oncogenes and tumour suppressors (H-RAS, KRAS, 
c-MYC, TP53) revealed in our array that are regulated in 
response to RAD51 expression levels. 
The role of transcriptional co-factor, a regulator 
of metastatic gene profiles makes RAD51 a possible 
biomarker and new therapeutic target. RAD51 has been 
suggested as possible biomarker to predict sensitivity to 
PARP1 inhibitor treatment and potential predictor for 
metastatic survival [37, 38]. We believe our findings have 
clinical implications for treating aggressive metastatic 
triple negative breast cancer and other cancers that have 
acquired overexpression of RAD51 and is the focus of 
ongoing work. 
MATERIALS AND METHODS
Clinical samples
Formalin-fixed paraffin embedded (FFPE) tumor 
blocks were retrieved from the archives of the Royal 
Brisbane and Women’s Hospital (Australia), Sullivan and 
Nicholades Pathology (Australia), various sources outlined 
previously[39] and the Kathleen Cuningham Foundation 
Consortium for research into Familial Breast Cancer 
(kConFab, Australia). There were several sets of samples 
analyzed, outlined in Table 1, including primary breast 
cancers and metastases on tissue microarrays (TMA): 
sporadic primary tumors (n=235), familial primary tumors 
(n=560), lymph node (LN) metastases (n=28), matched 
primary and brain metastases (n=39). For these cases the 
immunohistochemistry data for ER, PR and HER2 were 
available. We also analyzed 23 cases on whole sections, 
in which multiple stages of progression were analyzed: in 
situ carcinoma, invasive carcinoma, LN metastasis. The 
use of tumor samples was approved by the local research 
ethics committees.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on 
TMA sections, whole tissue sections and resected murine 
tumors to evaluate RAD51 protein expression in breast 
cancer. Sections were cut at 4 µm, mounted on silane-
coated slides and subjected to antigenic retrieval in EDTA 
[pH 8.0] for 2 minutes at 105oC. IHC was done using 
the anti-RAD51 primary antibody (SC 8349, Santa Cruz 
Biotech; 1:40 dilution, 2 hours incubation at 37C) and the 
MACH 2™ Polymer Detection system according to the 
manufacturer’s (Biocare Medical, Concord, CA, USA). 
Staining was visualized with 3,3’-Diaminobenzidine 
(DAB) and a haematoxylin counterstain. Germinal 
centre lymphocytes in normal lymph nodes served 
as a positive staining control for RAD51 due to the 
high rate of DNA repair associated immunoglobulin 
expression rearrangements. The staining was assessed 
semi-quantitatively by analysis of RAD51 positive cells 
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with nuclear staining of RAD51 rather than cytoplasmic 
considered positive, with additional arbitrary thresholds of 
intensity of staining, compared to positive controls. 
Cell culture, transfections and generation of 
inducible RAD51 knockdown and overexpression 
of RAD51 in cells
Breast cancer cell lines MDA-MB-231, BT549, 
Hs578t and the murine 4T1.2 were grown in DMEM media 
supplemented with 10% foetal bovine serum. All cell lines 
except 4T1.2 identity was confirmed by short tandem 
repeat (STR) profiling. Stealth siRNA (RAD51.1 and 
RAD51.2) and control siRNA oligos were purchased from 
Invitrogen. siRNAs were transfected using Lipofectamine 
2000 (Invitrogen) as per manufacturer’s instructions and 
samples were analyzed 48 hrs after transfection. Stable 
inducible knockdown cells were generated by integration 
of RAD51-mir (5’-CTCGGTACTGTGTTGTTCGTTA-3’) 
and scrambled-mir 
(5’-GTGTAACACGTCTATACGCCCA-3’) constructs 
into TMP-IRES-GFP vector and transfected into MDA-
MB-231 and 4T1.2 cell as described previously by 
Dickins et al.[40]. Overexpression was performed using 
Origene precision shuttle mammalian vector with full 
length human RAD51 and c-terminal tGFP tag and 
transfected using Lipofectamine 2000 (Invitrogen) as per 
manufacturer’s instructions. Cells were purified based on 
GFP expression.
Immunoblotting
Protein lysates were prepared via whole cell lysis 
in ice-cold lysis buffer (150mM NaCl, 10mM Tris-Cl 
pH 7.4, 5mM EDTA, 1% Triton X-100) supplemented 
with protease inhibitors (Leupeptin, Pepstatin and PMSF, 
Sigma Aldridge). Immunoblots were probed with anti-
RAD51 (Santa Cruz Biotech), anti-PARP (Millipore), anti-
PAR (BD Biosceinces), DNA-PK;P2609 (Cell Signaling) 
and anti-53BP1 (Bethyl), and with anti-Tubulin (Sigma) 
and anti-ß-Actin, (Sigma) as controls. Membranes were 
developed using fluorescent labeled secondary antibodies 
and visualized using the Odyssey system. Protein 
expression levels were determined by optical density 
versus actin loading controls using Image J software 
(NIH). 
In-vivo studies
Cohorts of 5 week old female nude NU-Foxn1nu 
or Balb/c mice established 40mm3 inguinal mammary fat 
pad tumors from 5x106 cells of MDA-MB-231/BT549 
or 1x106 cells of 4T1.2 into the left hind flank. Tumour 
were either retained or resected and the mice placed on a 
doxycycline water 4 µg/ml to induce knockdown. Non-
induced and empty vector (EV) cohorts served as controls. 
Tumor growth was monitored by caliper measurement and 
visualized using luciferase-mediated live animal imaging 
with the IVIS100 Xenogen system (Caliper Life Sciences).
In-vivo metastatic seeding
Female nude mice NU-Foxn1nu (5 weeks old) were 
injected intravenously with 1x106 doxycycline induced 
MDA-MB-231-RAD51mir or MDA-MB-231-SCRmir 
cells. Seeding of the lungs was visualized using luciferase-
mediated live animal imaging and monitored weekly for 
establishment of tumors. Mice remained on doxycycline 
water for the duration of the experiment.
Migration studies
3x104 cells were seeded in Xcelligence 16 well CIM-
transwell plate without serum (Roche) and monitored for 
20 -36 hours for migration towards a 20% serum gradient.
Metastatic gene expression Array
RNA was isolated from 5 µg/ml doxycycline 
induced and non-induced MDA-MB-231-RAD51mir or 
MDA-MB-231-SCRmir cells and Hs578T-EV (empty 
vector) and Hs578T-RAD51GFP using QIAGEN 
RNAEasy Mini Kit (Cat 74104). cDNA was synthesized 
using RT2 First Strand Kit (QIAGEN Cat 330401). cDNA 
was loaded in duplicate on The Human Tumor Metastasis 
RT² Profiler™ PCR Array containing 82 genes (QIAGEN-
Cat PAHS-028G-4) and analyzed on Roche Lightcycler 
480. Fold expression change was calculated against actin 
and expressed as base-two exponential increase in RNA 
levels (2ΔΔCt)+/- SEM.
Statistical methods
Statistical assessment of immunohistochemistry 
data was performed in GraphPad Prism V5.0c using 
Chi squared test with Yates correction (95% confidence 
interval) and Fisher’s exact test to compare RAD51 status 
between defined subgroups of samples. Significance of 
biological experiments was assessed with student t-tests 
(two tailed) +/-SEM.
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